KRAS Exon 2 Mutations in Patients with Sporadic Colorectal Cancer: Prevalence Variations in Mexican and Latin American Populations

被引：1

作者：

Venegas-Rodriguez, Jose Luis ^{[1
,2
]}

Hernandez-Sandoval, Jesus Arturo ^{[1
,2
]}

Gutierrez-Angulo, Melva ^{[1
,2
,3
]}

Moreno-Ortiz, Jose Miguel ^{[1
,2
]}

Gonzalez-Mercado, Anahi ^{[1
,2
]}

Peregrina-Sandoval, Jorge ^{[4
]}

Ramirez-Plascencia, Helen Haydee Fernanda ^{[5
]}

Flores-Lopez, Beatriz Armida ^{[6
]}

Alvizo-Rodriguez, Carlos Rogelio ^{[7
]}

Valenzuela-Perez, Jesus Alonso ^{[8
]}

Cervantes-Ortiz, Sergio ^{[8
]}

Ayala-Madrigal, Maria de la Luz ^{[1
,2
]}

机构：

[1] Univ Guadalajara, Ctr Univ Ciencias Salud, Inst Genet Humana Dr Enrique Corona Rivera, Guadalajara 44340, Jalisco, Mexico

[2] Univ Guadalajara, Ctr Univ Ciencias Salud, Programa Doctorado Genet Humana, Guadalajara 44340, Jalisco, Mexico

[3] Univ Guadalajara, Ctr Univ Altos, Dept Ciencias Salud, Tepatitlan De Morelos 47600, Jalisco, Mexico

[4] Univ Guadalajara, Ctr Univ Ciencias Biol & Agr, Dept Biol Celular & Mol, Zapopan 44600, Jalisco, Mexico

[5] Univ Autonoma Guadalajara, Fac Med, Decanato Ciencia Salud, Zapopan 45129, Jalisco, Mexico

[6] Univ Autonoma Guadalajara, Fac Med, Dept Ciclo Vida, Zapopan 45129, Jalisco, Mexico

[7] Benemerita Univ Autonoma Puebla, Fac Med, Puebla 72420, Mexico

[8] Hosp Civil Dr Juan I Menchaca, Serv Colon & Recto, Guadalajara 44340, Jalisco, Mexico

来源：

CANCERS | 2024年 / 16卷 / 13期

关键词：

colorectal cancer; KRAS gene; exon; 2; mutation; Latin American genetic variations; GENE MUTATION; CODON; 12; FEATURES; BRAF;

D O I：

10.3390/cancers16132323

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary: KRAS is one of the most prominent driver genes implicated in colorectal cancer (CRC), with mutations detected in 33% to 50% of CRC patients. Exon 2 harbors up to 98% of these mutations. Variants in this gene play crucial roles in the progression of the disease, influencing its development, clinical manifestations, and treatment election. This study elucidates a 17% prevalence of mutations in KRAS exon 2 among western Mexican patients with sporadic CRC. Furthermore, a 30% pooled prevalence of mutations in KRAS exon 2 was determined after analyzing an additional 16 studies from Latin America, encompassing 12,604 CRC patients. Due to advances in precision medicine treatments, knowing the pathogenic status of the KRAS gene will become imperative to optimally select targeted therapies. We searched for the prevalence of actionable somatic mutations in exon 2 of the KRAS gene in western Mexican patients with CRC. Tumor tissue DNA samples from 150 patients with sporadic CRC recruited at the Civil Hospital of Guadalajara were analyzed. Mutations in exon 2 of the KRAS gene were identified using Sanger sequencing, and the data were analyzed considering clinical-pathological characteristics. Variants in codon 12 (rs121913529 G>A, G>C, and G>T) and codon 13 (rs112445441 G>A) were detected in 26 patients (with a prevalence of 17%). No significant associations were found between these variants and clinical-pathological characteristics (p > 0.05). Furthermore, a comprehensive search was carried out in PubMed/NCBI and Google for the prevalence of KRAS exon 2 mutations in Latin American populations. The 17 studies included 12,604 CRC patients, with an overall prevalence of 30% (95% CI = 0.26-0.35), although the prevalence ranged from 13 to 43% across the different data sources. Determining the variation and frequency of KRAS alleles in CRC patients will enhance their potential to receive targeted treatments and contribute to the understanding of the genomic profile of CRC.

引用

页数：10

共 54 条

[31] KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges [J].